News

Remdesivir produced by Gilead was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.

Read more:
https://cyclodextrinnews.com/2020/04/21/gileads-remdesivir-significantly-reduces-covid-19-symptoms-in-rhesus-monkeys-in-nih-trial/
https://cyclodextrinnews.com/2020/02/27/gilead-sciences-initiates-two-phase-3-studies-of-investigational-sbecd-enabled-antiviral-remdesivir-for-the-treatment-of-covid-19/
https://cyclodextrinnews.com/2020/02/03/gilead-uses-sbecd-enabled-remdesivir-gs-5734-for-treating-the-first-case-of-the-2019-novel-coronavirus-in-the-united-states/
https://cyclodextrinnews.com/2020/04/17/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/

BACK TO NEWS